Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma

Oncotarget

Volumn 6, Issue 30, 2015, Pages 29555-29572

  Yeh, Chia Ming ^a   Chen, Pi Che ^b   Hsieh, Hsiao Yen ^a,b   Jou, Yeong Chin ^b   Lin, Chang Te ^b   Tsai, Ming Hsuan ^a   Huang, Wen Yu ^a   Wang, Yi Ting ^a   Lin, Ru Inn ^a,c   Chen, Szu Shan ^a   Tung, Chun Liang ^b   Wu, Shu Fen ^a   Chang, De Ching ^a   Shen, Cheng Huang ^b   Hsu, Cheng Da ^b   Chan, Michael W Y ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^b CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

DNA methylation; Urine; Urothelial carcinoma; ZNF671

Indexed keywords

INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; SECRETED FRIZZLED RELATED PROTEIN 1; STEM CELL FACTOR; TRANSCRIPTION FACTOR NANOG; DNA; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; ZNF671 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLADDER; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; DOWN REGULATION; EPIGENETIC REPRESSION; FEMALE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IRF8 GENE; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY; SFRP1 GENE; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR INVASION; TUMOR SUPPRESSOR GENE; URINARY TRACT; ZNF671 GENE; ANIMAL; BAGG ALBINO MOUSE; BLADDER TUMOR; CHEMISTRY; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR VOLUME; URINE; XENOGRAFT;

ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84945162360     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4986     Document Type: Article

References (57)

1. Ploeg M, Aben KK and Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27:289-293.
2. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
3. Chen CJ, Chuang YC, Lin TM and Wu HY. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res. 1985; 45:5895-5899.
4. Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS and Shariat SF. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol. 2013; 189:1214-1221.
5. Tan LB, Chang LL, Cheng KI, Huang CH and Kwan AL. Transitional cell carcinomas of the renal pelvis and the ureter: comparative demographic characteristics, pathological grade and stage and 5-year survival in a Taiwanese population. BJU Int. 2009; 103:312-316.
6. Williams SG and Stein JP. Molecular pathways in bladder cancer. Urol Res. 2004; 32:373-385.
7. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49:466-465; discussion 475-467.
8. Prasad SM, Decastro GJ and Steinberg GD. Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol. 2011; 8:631-642.
9. Hansen MF and Cavenee WK. Tumor suppressors: recessive mutations that lead to cancer. Cell. 1988; 53:173-174.
10. Hunter T. Oncoprotein networks. Cell. 1997; 88:333-346.
11. Jones PA and Baylin SB. The epigenomics of cancer. Cell. 2007; 128:683-692.
12. Baylin SB and Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer. 2011; 11:726-734.
13. Seisenberger S, Peat JR and Reik W. Conceptual links between DNA methylation reprogramming in the early embryo and primordial germ cells. Curr Opin Cell Biol. 2013; 25:281-288.
14. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003; 3:253-266.
15. Tung PY and Knoepfler PS. Epigenetic mechanisms of tumorigenicity manifesting in stem cells. Oncogene. 2015; 34:2288-2296.
16. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol. 2003; 4:351-358.
17. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM and To KF. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002; 8:464-470.
18. Chen PC, Tsai MH, Yip SK, Jou YC, Ng CF, Chen Y, Wang X, Huang W, Tung CL, Chen GC, Huang MM, Tong JH, Song EJ, Chang DC, Hsu CD, To KF, et al. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics. 2011; 4:45.
19. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM and Jones PA. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995; 55:4531-4535.
20. Kandimalla R, van Tilborg AA, Kompier LC, Stumpel DJ, Stam RW, Bangma CH and Zwarthoff EC. Genomewide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur Urol. 2012; 61:1245-1256.
21. Ibragimova I, Dulaimi E, Slifker MJ, Chen DY, Uzzo RG and Cairns P. A global profile of gene promoter methylation in treatment-naive urothelial cancer. Epigenetics. 2014; 9:760-773.
22. Huang da W, Sherman BT and Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37:1-13.
23. Arai E, Chiku S, Mori T, Gotoh M, Nakagawa T, Fujimoto H and Kanai Y. Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis. 2012; 33:1487-1493.
24. Hansel A, Steinbach D, Greinke C, Schmitz M, Eiselt J, Scheungraber C, Gajda M, Hoyer H, Runnebaum IB and Durst M. A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women. PLoS One. 2014; 9:e91905.
25. Cheng Y, Geng H, Cheng SH, Liang P, Bai Y, Li J, Srivastava G, Ng MH, Fukagawa T, Wu X, Chan AT and Tao Q. KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res. 2010; 70:6516-6526.
26. Cheng Y, Liang P, Geng H, Wang Z, Li L, Cheng SH, Ying J, Su X, Ng KM, Ng MH, Mok TS, Chan AT and Tao Q. A novel 19q13 nucleolar zinc finger protein suppresses tumor cell growth through inhibiting ribosome biogenesis and inducing apoptosis but is frequently silenced in multiple carcinomas. Mol Cancer Res. 2012; 10:925-936.
27. Severson PL, Tokar EJ, Vrba L, Waalkes MP and Futscher BW. Coordinate H3K9 and DNA methylation silencing of ZNFs in toxicant-induced malignant transformation. Epigenetics. 2013; 8:1080-1088.
28. Eads CA and Laird PW. Combined bisulfite restriction analysis (COBRA). Methods Mol Biol. 2002; 200:71-85.
29. Baylin S and Bestor TH. Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell. 2002; 1:299-305.
30. Kong D, Li Y, Wang Z and Sarkar FH. Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel). 2011; 3:716-729.
31. Bedi U, Mishra VK, Wasilewski D, Scheel C and Johnsen SA. Epigenetic plasticity: a central regulator of epithelialto-mesenchymal transition in cancer. Oncotarget. 2014; 5:2016-2029.
32. McDonald OG, Wu H, Timp W, Doi A and Feinberg AP. Genome-scale epigenetic reprogramming during epithelialto-mesenchymal transition. Nat Struct Mol Biol. 2011; 18:867-874.
33. Pirozzi G, Tirino V, Camerlingo R, Franco R, La Rocca A, Liguori E, Martucci N, Paino F, Normanno N and Rocco G. Epithelial to mesenchymal transition by TGFbeta-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One. 2011; 6:e21548.
34. Su SF, de Castro Abreu AL, Chihara Y, Tsai Y, AndreuVieyra C, Daneshmand S, Skinner EC, Jones PA, Siegmund KD and Liang G. A panel of three markers hyper-and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res. 2014; 20:1978-1989.
35. Witzgall R, O'Leary E, Leaf A, Onaldi D and Bonventre JV. The Kruppel-associated box-A (KRAB-A) domain of zinc finger proteins mediates transcriptional repression. Proc Natl Acad Sci U S A. 1994; 91:4514-4518.
36. Margolin JF, Friedman JR, Meyer WK, Vissing H, Thiesen HJ and Rauscher FJ, 3rd. Kruppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci U S A. 1994; 91:4509-4513.
37. Urrutia R. KRAB-containing zinc-finger repressor proteins. Genome Biol. 2003; 4:231.
38. Underhill C, Qutob MS, Yee SP and Torchia J. A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1. J Biol Chem. 2000; 275:40463-40470.
39. Schultz DC, Friedman JR and Rauscher FJ, 3rd. Targeting histone deacetylase complexes via KRAB-zinc finger proteins: the PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of the Mi-2alpha subunit of NuRD. Genes Dev. 2001; 15:428-443.
40. Schultz DC, Ayyanathan K, Negorev D, Maul GG and Rauscher FJ, 3rd. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev. 2002; 16:919-932.
41. Sripathy SP, Stevens J and Schultz DC. The KAP1 corepressor functions to coordinate the assembly of de novo HP1-demarcated microenvironments of heterochromatin required for KRAB zinc finger protein-mediated transcriptional repression. Mol Cell Biol. 2006; 26:8623-8638.
42. Friedman JR, Fredericks WJ, Jensen DE, Speicher DW, Huang XP, Neilson EG and Rauscher FJ, 3rd. KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev. 1996; 10:2067-2078.
43. Moosmann P, Georgiev O, Le Douarin B, Bourquin JP and Schaffner W. Transcriptional repression by RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1. Nucleic Acids Res. 1996; 24:4859-4867.
44. Zheng L, Pan H, Li S, Flesken-Nikitin A, Chen PL, Boyer TG and Lee WH. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell. 2000; 6:757-768.
45. Huang C, Jia Y, Yang S, Chen B, Sun H, Shen F and Wang Y. Characterization of ZNF23, a KRAB-containing protein that is downregulated in human cancers and inhibits cell cycle progression. Exp Cell Res. 2007; 313:254-263.
46. Hu R, Peng G, Dai H, Breuer EK, Stemke-Hale K, Li K, Gonzalez-Angulo AM, Mills GB and Lin SY. ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res. 2011; 71:6524-6534.
47. Monteiro-Reis S, Leca L, Almeida M, Antunes L, Monteiro P, Dias PC, Morais A, Oliveira J, Henrique R and Jeronimo C. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. Eur J Cancer. 2014; 50:226-233.
48. Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Bohle A, Van Rhijn BW, Kaasinen E, Palou J and Shariat SF. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013; 63:1059-1071.
49. Frietze S, O'Geen H, Blahnik KR, Jin VX and Farnham PJ. ZNF274 recruits the histone methyltransferase SETDB1 to the 3' ends of ZNF genes. PLoS One. 2010; 5:e15082.
50. O'Geen H, Squazzo SL, Iyengar S, Blahnik K, Rinn JL, Chang HY, Green R and Farnham PJ. Genome-wide analysis of KAP1 binding suggests autoregulation of KRAB-ZNFs. PLoS Genet. 2007; 3:e89.
51. Lin LF, Li CF, Wang WJ, Yang WM, Wang DD, Chang WC, Lee WH and Wang JM. Loss of ZBRK1 contributes to the increase of KAP1 and promotes KAP1-mediated metastasis and invasion in cervical cancer. PLoS One. 2013; 8:e73033.
52. Cairns P. Gene methylation and early detection of genitourinary cancer: the road ahead. Nat Rev Cancer. 2007; 7:531-543.
53. Jeronimo C and Henrique R. Epigenetic biomarkers in urological tumors: A systematic review. Cancer Lett. 2014; 342:264-274.
54. Planz B, Jochims E, Deix T, Caspers HP, Jakse G and Boecking A. The role of urinary cytology for detection of bladder cancer. Eur J Surg Oncol. 2005; 31:304-308.
55. Christian BJ, Loretz LJ, Oberley TD and Reznikoff CA. Characterization of human uroepithelial cells immortalized in vitro by simian virus 40. Cancer Res. 1987; 47:6066-6073.
56. Chou JL, Huang RL, Shay J, Chen LY, Lin SJ, Yan PS, Chao WT, Lai YH, Lai YL, Chao TK, Lee CI, Tai CK, Wu SF, Nephew KP, Huang TH, Lai HC, et al. Hypermethylation of the TGF-beta target, ABCA1 is associated with poor prognosis in ovarian cancer patients. Clin Epigenetics. 2015; 7:1.
57. Lin HY, Hung SK, Lee MS, Chiou WY, Huang TT, Tseng CE, Shih LY, Lin RI, Lin JM, Lai YH, Chang CB, Hsu FC, Chen LC, Tsai SJ, Su YC, Li SC, et al. DNA methylome analysis identifies epigenetic silencing of FHIT as a determining factor for radiosensitivity in oral cancer: an outcome-predicting and treatment-implicating study. Oncotarget. 2015; 6:915-934.